Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)

NCT00609401 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Disease
Renal Cell Carcinoma

Interventions

DRUG: Nexavar (Sorafenib)
DRUG: IL-2

Sponsor

Italian Trial in Medical Oncology